Objective: Aggregation of a-synuclein (a-syn) and a-syn cytotoxicity are hallmarks of sporadic and familial Parkinson disease (PD), with accumulating evidence that prefibrillar oligomers and protofibrils are the pathogenic species in PD and related synucleinopathies. Peroxisome proliferator-activated receptor c coactivator 1a (PGC-1a), a key regulator of mitochondrial biogenesis and cellular energy metabolism, has recently been associated with the pathophysiology of PD. Despite extensive effort on studying the function of PGC-1a in mitochondria, no studies have addressed whether PGC-1a directly influences oligomerization of a-syn or whether a-syn oligomers impact PGC-1a expression.
P
arkinson disease (PD) is an adult onset neurodegenerative disease characterized by a-synuclein (a-syn) neuropathology and progressive neuronal loss in the substantia nigra pars compacta (SN). The a-syn neuropathology spreads widely in addition to the SN also to other brain areas, for example, large parts of the peripheral autonomic nervous system in early stages or the cerebral cortex in later stages. 1 The characteristic a-syn immunoreactive inclusions are termed Lewy bodies or Lewy neurites and contain fibrillar aggregates of a-syn as a main component. 2 A recent growing body of evidence, however, suggests that prefibrillar oligomers are the key contributors to the development of PD. [3] [4] [5] [6] [7] a-syn oligomers and prefibrillar forms, rather than mature fibrils, have recently been shown to induce cell death in vitro 8 and in vivo 9 and are thus regarded as the pathogenic species in PD. [10] [11] [12] [13] Little is known about how and why a-syn oligomers form. Reactive oxygen species (ROS) increase a-syn oligomer formation, and mitochondrial alterations, [14] [15] [16] leading to further increased ROS production, are associated with degeneration of midbrain dopamingergic neurons. 17 PD pathogenesis is intricately linked to mitochondrial dysfunction and oxidative stress. [18] [19] [20] Inhibiting complex I of the mitochondrial respiratory chain in dopaminergic neuronal cells reproduces many features of PD including a-syn inclusions in rats. 21 Administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), also targeting mitochondrial complex I, causes acute and permanent PD in humans 22 and has been used to generate experimental models of PD in animals and in cell culture studies. [23] [24] [25] Several studies demonstrated that genes regulating mitochondrial function or oxidative stress influence the risk of PD. [26] [27] [28] One of the major regulators of mitochondrial biogenesis and energy metabolism in cells is the peroxisome proliferator-activated receptor c coactivator 1a (PGC1a). 29 PGC-1a controls oxidative phosphorylation, antioxidant defense, 30 and autophagy. 31 Recent studies identified different tissue-specific isoforms of PGC-1a, including muscle-specific and central nervous system (CNS)-specific (CNS-PGC-1a) isoforms. 32, 33 The reference gene of PGC-1a (RG-PGC-1a) has been reported as an important key player in several neurodegenerative diseases. 34 Restoration of PGC-1a expression ameliorates the symptoms in a mouse model of Huntington disease (HD) by promoting the elimination of huntingtin aggregates. 31 Additionally, several studies point to PGC-1a as a modifier of HD [35] [36] [37] [38] ; however, there is also 1 study questioning this association. 39 Moreover, transgenic overexpression of PGC-1a in mice improves motoneuron function and extends lifespan in the SOD1-G93A mouse model of amyotrophic lateral sclerosis (ALS). 40, 41 In line with these studies, we have previously shown that RG-PGC-1a deficiency leads to an earlier age of onset and shortened survival in ALS male mice. 42 Only a few studies have addressed PGC-1a in the context of PD, and its relevance for PD is poorly understood. Genes that are regulated by PGC-1a are underexpressed in PD brains 43 ; however, whether RG-PGC-1a itself or CNS-PGC-1a are deregulated in PD, that is, expressed above or below a physiological range, is not known thus far. A tight regulation of PGC-1a in the nigrostriatal system has been shown to be crucial for maintenance of dopaminergic neurons under physiological conditions. 44 In mice, repression of PGC-1a kills dopaminergic neurons, and PGC-1a activation can prevent this loss. 45 Interestingly, a-syn is able to reduce PGC-1a expression by direct interaction with its promoter, 46 and PGC-1a restoration improves survival of neurons overexpressing the mutated a-syn. 47 Together, existing data from the literature point to a vicious circle between PGC1a dysfunction and asyn oligomerization and toxicity. To test the hypothesis that PGC1a dysfunction and a-syn oligomerization influence each other and/or create a vicious circle, we set out to determine how PGC-1a affects a-syn-mediated toxicity, and more importantly, whether PGC-1a impacts asyn oligomerization. Conversely, we examined whether asyn oligomers could influence RG-PGC-1a or CNS-PGC-1a expression. To address these questions, we used human PD patient material, a mouse model for PD, and a PD cell culture model to determine whether different isoforms of PGC-1a were deregulated in PD. Furthermore, using an a-syn protein complementation assay, we explored whether PGC-1a directly influences a-syn oligomer formation and a-syn-mediated toxicity.
Materials and Methods

Human Samples
Fresh frozen human brain tissue from the SN was used for the determination of mRNA levels of RG-PGC-1a and CNS-PGC1a. All PD patients were diagnosed using the UK PD Society Brain Bank clinical diagnostic criteria at specialized centers for PD. Neuropathological diagnosis demonstrated the presence of Lewy body pathology in the SN with typical pathological features. 1 We used SN tissue from cases with Braak stage 5 and 6.
In PD Braak stage 5, the lesions advance from the temporal mesocortex to adjacent high-order sensory association areas of the neocortex. In PD Braak stage 6, the neocortical pathology proceeds further, that is, into the first-order sensory association areas of the neocortex and, sometimes, into the neocortical primary sensory and motor fields. 1 The brain samples were received from the brain bank of Ulm University; University of California, San Diego; and the Mayo Clinic, Jacksonville, Florida. All human experiments were performed in accordance with the declaration of Helsinki and approved by the respective local research ethics committees.
Animals
Thy-1 (A30P) a-syn mice 48, 49 genotyping was performed as described previously. 48, 49 Mice were maintained in a temperature-and humidity-controlled environment at 23 C with a 12-hour light/dark cycle and had food and water ad libitum. Thy-1 a-syn A30P mice were repeatedly tested for a-syn expression on mRNA level and protein level. Moreover, the typical phenotype including impaired balance, hind limb clasping, and a reduced position reflex as described earlier [49] [50] [51] was observed in our mice starting at 16 months of age. As an additional quality control for our mouse cohort, proteinase K PET blots (as described previously 49 ) confirmed a-syn pathology beginning at the age of 12 months with interindividual variation. Most importantly, the a-syn pathology was consistently seen in Thy-1 a-syn A30P mice at the age of 18 months (data not shown). For biochemical analysis, animals were sacrificed and tissues were quickly dissected, frozen in liquid nitrogen, and stored at 280 C until use. RG-PGC-1a-deficient mice used in this study were described earlier. 52 
Plasmids
Plasmids used in this study such as fusion constructs a-synhGLuc1 (S1) and a-syn-hGLuc2 (S2) as well as PGC-1a plasmid have been described previously. [53] [54] [55] Lentiviral vectors used the human p6IPZ Library from Open Biosystems (Lafayette, CO). Therefore, the target sequences were designed by using an algorithm approach (ShPGC-1a-A: TGCTGTTGACAGTGAGCGCGCCAACACTCAGCTAAGTT ATTAGTGAAGCCACAGATGTAATAACTTAGCTGAGTGTT GGCTTGCCTACTGCCTCGGA; ShPGC-1a-B: TGCTGTTG ACAGTGAGCGACGTGTGATTTATGTCGGTAAATAGTGA AGCCACAGATGTATTTACCGACATAAATCACACGGTGCC TACTGCCTCGGA).
Primary Cortical Neuron Cultures
Primary cortical neurons were cultured from E16 embryos issued from a cross between 2 homozygous RG-PGC-1a knockout (KO) or wild-type mice. After mechanical dissociation, cells were resuspended in Neurobasal (NB; Gibco, Darmstadt, Germany) medium supplemented with 10% fetal bovine serum, 2mM GlutaMAX (Life Technologies, Grand Island, NY), 100U/ml penicillin, and 100lg/ml streptomycin and plated at a density of 3.84 3 10 4 cells/well on 96-well plates (Corning, Corning, NY), 60mm dishes at a density of 3.6 3 10 6 cells/ dish (Corning CoStar, Corning, NY) coated with 20lg/ml poly-D-lysine (Sigma-Aldrich, St Louis, MO). After 2 hours, medium was changed to NB/B-27 (NB medium containing 2% [vol/vol] B-27 supplement), 100U/ml penicillin, 100lg/ml streptomycin, and 2mM/l glutamine and grown at 37 C in 5% CO 2 . Medium was changed every third day partially. Neurons were grown for 4 to 5 days in vitro before being infected with AAV8-S1/AAV8-S2 or treated with conditioned media from S1/S2-transfected H4 cells For reuptake experiments, conditioned media from S1/ S2-transfected H4 cells was collected 48 hours post-transfection and centrifuged for 5 minutes at 3,000 3 g to eliminate floating cells before being transferred to naive primary neurons for the indicated time. Primary neurons were treated with a 1:1 ratio of conditioned media containing a-syn oligomers and neuronal culture media
Toxicity Assay
Toxicity was analyzed 1 to 2 days after S1/S2 transfection or after treatment with conditioned media from S1/S2-transfected H4 cells by using either the ToxiLight BioAssay Kit (Lonza, Rockland, ME), which quantitatively measures the release of adenylate kinase from damaged cells, or by using Apo-ONE homogeneous caspase-3/7 assay (Promega), measuring the activity of caspases 3 and 7 using a fluorometric substrate Z-DEVD-rhodamine 110 according to the respective manufacturers' instructions. Viability was evaluated by using the CellTiter-Glo Luminescent Cell Viability Assay (Promega), which quantifies the amount of adenosine triphosphate, an indicator of metabolically active cells.
Gaussia Luciferase Protein-Fragment Complementation Assay
H4 cells were transfected with S1 and S2 in a white 96-well plate as described above. At 24 hours after transfection, culture media was removed and cells were washed with phosphatebuffered saline (PBS) and placed in OPTI-MEM (Gibco) for measurement. Luciferase activity from protein complementation was measured for conditioned media and live cells in an automated plate reader (Perkin-Elmer, Waltham, MA) at 480nm following the injection of the cell permeable substrate, coelenterazine (20lM; Prolume, Pinetop, AZ) with a signal integration time of 2 seconds.
Adeno-Associated Virus Vector Construction and Production
The viral vectors rAAV-CBA-SYNUCLEIN-LUC1-WPRE (S1) and rAAV-CBA-SYNUCLEIN-LUC2-WPRE (S2) used in this study were described previously.
53,54
Lentiviral Production
Lentivirus was produced in 293T HEK cells after transfection of 15lg shRNA plasmid, 10lg human immunodeficiency virus-gag/pol, and 5lg vesicular stomatitis virus G glycoprotein using a calcium-phosphate method in DMEM supplemented with 10% fetal calf serum (FCS) in 10cm dishes. After 8 to 12 hours transfection, cells were washed in PBS and fresh cell culture media containing DMEM with 10% FCS was added. Supernatants were harvested after 24 and 48 hours and filtrated through 0.22mm filters. Human H4 neuroglioma were plated in 10cm dishes and infected using 50% supernatant lentiviral particles and culture medium containing 8lg/ml Polybrene. After approximately 10 hours of incubation, cells were washed in PBS and medium was changed to fresh complete medium. Two days post-transduction, cells were placed into fresh complete medium containing 1lg/ml puromycin for 4 days. Selection medium containing 1lg/ml puromycin was changed every 2 days. Efficiency of the transduced cultures, that is, percentage of green fluorescent protein (GFP)-expressing cells, was estimated using flow cytometry analysis, and gene knockdown was evaluated by quantitative polymerase chain reaction (qPCR). After puromycin selection, cells were counted and plated at the density of 500 cells per well into 12-well plates.
Real-Time qPCR
Total RNA was extracted using the RNeasy Mini Plus Kit (Qiagen, Hamburg, Germany) in accordance with the manufacturer's instructions. Briefly, cell cultures were disrupted directly into the buffer RLT (Qiagen) supplemented with 10% b-mercaptoethanol (Sigma-Aldrich, Taufkirchen, Germany). For RNA extraction from tissue, frozen tissues were placed into a tube containing a 5mm stainless steel bead. Working on ice, 700lL of buffer RLT supplemented with 10% b-mercaptoethanol was added, and homogenization was performed in a TissueLyser (Qiagen, Valencia, CA) at 30Hz for 3 minutes. After RNA extraction, RNA concentration was measured using a nanodrop (Thermo Scientific, Waltham, MA) and 1lg of total RNA was used to synthesize cDNA using I-script reverse transcriptase (Bio-Rad Laboratories, Munich, Germany) containing oligo-dT primers and random primers. cDNA was then diluted 10 times and PCR analysis was performed on a Bio-Rad iCycler System using iQSYBR Green Supermix (BioRad Laboratories). A specific standard curve was performed in parallel for each gene to assess the specificity of the products, for quantification of the respective transcripts in duplicate. PCR conditions were 3 minutes at 94 C, followed by 40 cycles of 45 seconds at 94 C and 10 seconds at 60 C. The relative level of each RNA was normalized to the 2 housekeeping genes polymerase (RNA) II polypeptide A (POLR2A) and TATA box binding protein (TBP). These housekeeping genes have been thoroughly validated and turned out to be extremely stable in our previous studies. 42, 56, 57 CFX Manager software (Bio-Rad Laboratories) was used to analyze our data. Briefly, relative quantification was achieved by calculating the ratio between the cycle number at which the signal crossed a threshold set within the logarithmic phase of the gene of interest and that of genes used for normalization calculated by the relative quantity of the reference genes CNS-and RG-specific Ppargc1a transcripts were quantified using primers targeting CNS-specific exons B1 and B4 33 and exons 1 and 2, respectively. PGC-1ß transcripts were quantified using PGC-1ß-specific primers. Human primers were PGC-1a B1/B4: forward TACAACTACGGCTCCTCCTGG, reverse TACCCTTCATCCATGGGGCTC; PGC-1a Ex1/Ex2: forward CTTGGGACATGTGCAGCCAAG, reverse GCTGTC TGTATCCAAGTCAT; PGC-1ß: forward AAATCTCAAGGG GAGCGTGG, reverse AGATGCTCCAAGCCAATGCT; polymerase II: forward TTGTGCAGGACACACTCACA, reverse CAGGAGGTTCATCACTTCACC; TBP: forward CCCATGA CTCCCATGACC, reverse TTTACAACCAAGATTCACTG TGG; transcription factor A, mitochondrial (TFAM): forward AAGCTCAGAACCCAGATGCAA, reverse CAGGAAGTTCC CTCCAACGC; transcription factor EB (TFEB): forward ACCCTGAGAGGGAGTTGGAT, reverse GGCATCTGCATT TCAGGATT. Mouse primers were PGC-1a B1/B4: forward TACAACTACGGCTCCTCCTGG, reverse TACCCTTCATC CATGGGGCTC; PGC-1a: forward AGAGTGTGCTGCTCT GGTTG, reverse TTCCGATTGGTCGCTACACC; polymerase II: forward GCTGGGAGACATAGCACCA, reverse TTAC TCCCCTGCATGGTCTC; TBP: forward GGCGGTTTGGC TAGGTTT, reverse GGGTTATCTTCACACACCATGA.
A Linear Mixed Effects Model for Estimating Disease, Age, Gender, and Postmortem Interval Effects
Similar to the method from Schlaudraff et al, 58 we have applied a linear mixed effects model analysis to our gene expression data. This allowed us to estimate possible confounding effects by covariates such as age, gender, and postmortem interval (PMI). The following model was fit to the natural logarithm of relative expression data for RG-PGC-1a (formula in Wilkinson notation 59 ):
logðPGC1a RG Þ 11group1sex1age1PMI1ð1jbatchÞ
Herein the group effect represents control or PD and sex represents the gender (male or female). Random effects were introduced on the intercept to calibrate for differences between different batches of samples that were measured on different PCR plates. The analysis was performed with the LinearMixedModel class of the Statistics Toolbox for Matlab v8.2 (MathWorks, Natick, MA), which fitted the model by likelihood maximization.
Western Blotting
Cells or human brain tissue were lysed in radioimmunoprecipitation assay buffer (150mM NaCl, 1.0% IGEPAL, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS] , and 50mM Tris, pH 8.0) and protease inhibitor cocktail, 1 tablet/ 10ml (Roche Diagnostics, Mannheim, Germany). Protein quantification was carried out using a BCA assay kit (Thermo Scientific, Bonn, Germany). Equal amounts of soluble proteins were denatured by boiling, resolved by 9% SDS polyacrylamide gel electrophoresis. After transfer to nitrocellulose membrane (Protran; Schleicher and Schuell BioScience, Whatman Group, Dassel, Germany) membranes were blocked with 10% nonfat dry milk in Tris-buffered saline with Tween (TBS-T) for 30 minutes at room temperature. Membranes were then incubated with primary antibodies (mouse anti-a-syn, 1:1,000, BD Transduction, Heidelberg, Germany; mouse antiactin, monoclonal, 1:500, Cell Signaling Technology, Frankfurt, Germany; homemade rabbit anti-PGC-1a, 1:500, Eurogentec, Cologne, Germany) overnight at 4 C. After three 5-10-minute TBS-T washes, membranes were incubated at room temperature for 1 hour with horse radish peroxidase-conjugated secondary antibody (antimouse; 1:10,000; Invitrogen, Freiburg, Germany). After three 5-to 10-minute TBS-T washes, immunoblots were analyzed using ECL chemiluminescent detection system 
The table summarizes the characteristics of PD patients and controls from Ulm University; University of California, San Diego; and Mayo Clinic Jacksonville who have come to postmortem examination. and CNS-PGC-1a (E) in the brainstem of wild-type (wt; 1/1) and (Thy-1)-A30P a-syn mice at the indicated age (in months). 1/1 mice are represented by white columns, (Thy-1)-A30P a-synuclein mice by black columns. RG-PGC-1a and CNS-PGC-1a transcripts were normalized to POLR2A and TBP levels. *p < 0.05, **p < 0.01, ***p < 0.001, n 5 4-6 animals per group. (F, G) mRNA levels of RG-PGC-1a (F) and CNS-PGC-1a (G) in the cortex from wt (1/1) and (Thy-1)-A30P a-syn mice. mRNA transcripts were normalized to POLR2A and TBP levels, *p < 0.05, **p < 0.01, n 5 4-6 per group. 1/1 mice are represented by white columns, (Thy-1)-A30P a-syn mice by black columns. (H, I) mRNA levels of RG-PGC-1a (H) and CNS-PGC-1a (I) in wt primary neurons coinfected with adeno-associated virus (AAV) a-syn-hGLuc1 (S1)/AAV a-syn-hGLuc2 (S2) or control for 3 days. Four independent experiments were performed. mRNA transcripts were normalized to POLR2A and TBP levels. **p < 0.01. (J) mRNA levels of RG-PGC-1a in H4 transiently cotransfected with S1/S2 for 48 hours. Three independent experiments were performed. **p < 0.01. (K) mRNA levels of CNS-PGC-1a in H4 transiently cotransfected with S1/S2 for 48 hours.
Three independent experiments were performed. mRNA levels were standardized using POLR2A and TBP levels.
(Amersham/GE HealthCare, Chalfont St Giles, UK). Densitometric quantification was performed using ImageJ software (http://rsb.info.nih.gov/ij/).
Autophagosome Detection
The Premo Autophagy Sensor Kit (Invitrogen) was employed for autophagosome detection, according to the guidelines. Briefly, H4 cells were transfected with the indicated constructs using Superfect (Qiagen, Chatsworth, CA), and 24 hours afterwards, they were transduced with BacMam LC3B-GFP with a multiplicity of infection equal to 10, using 5 3 10 4 cells in 4-well Cell Culture Chambers (Sarstedt, N€ umbrecht, Germany) for 24 hours. An inverted fluorescence microscope (Axio Observer-A1; Zeiss, G€ ottingen, Germany) was employed for live cell imaging using 360 magnification. Quantification of autophagosome was performed using the ImageJ AUTO-COUNTER plugin as described previously. 60 
Statistical Analysis
Statistical comparisons were accomplished with the unpaired Mann-Whitney-Wilcoxon test for comparison of 2 groups or analysis of variance followed by the post hoc Tukey test for multiple comparisons using PRISM v6.0 software (GraphPad, San Diego, CA).
Results
Repression of PGC-1a in PD Patients, and In Vivo and In Vitro Models for Synucleinopathies Because PGC-1a-dependent genes have been shown to be downregulated in the brains of PD patients, 43 we asked whether the RG-PGC-1a itself and CNS-PGC-1a transcripts are regulated in PD. Real-time (RT) qPCR was performed in postmortem tissue from the SN of PD patients and non-PD controls. Neuropathological diagnosis demonstrated the presence of Lewy body pathology in the SN (from patients with PD Braak stages 5 and 6; see Materials and Methods section and Table) . We found expression of the RG-PGC-1a reduced by nearly 70% in the SN of PD patients (Fig 1A) , whereas the CNS-PGC1a was unchanged in the SN of PD patients (see Fig  1B) . Although control and PD samples were well matched with respect to age and PMI with no significant differences (age: 72.2 6 3.76 vs 74.5 6 1.45 years, p 5 0 Table) . Furthermore, Western blot analysis with a PGC-1a-specific antibody that does not distinguish between RG-or CNS-PGC-1a confirmed a reduction of PGC-1a in SN of PD patients at the protein level (see Fig 1C) .
To gain insight into the mechanisms underlying the PGC-1a deregulation in PD, we turned to a wellcharacterized transgenic mouse model overexpressing the human PD-associated A30P a-syn mutation. 48, 49 FIGURE 3: Peroxisome proliferator-activated receptor c coactivator 1a (PGC-1a) reference gene (RG-PGC-1a) and central nervous system-specific PGC-1a (CNS-PGC-1a) knockdown increases a-synuclein (a-syn) oligomerization and resulting toxicity. (A) Real-time quantitative polymerase chain reaction (RT-qPCR) analysis of RG-PGC-1a from H4 cells cotransfected with a-syn-hGLuc1 (S1)/a-syn-hGLuc2 (S2) and the 2 independent shRNAs (ShPGC-1a-A and ShPGC-1a-B.). mRNA levels were standardized using polymerase (RNA) II polypeptide A (POLR2A) and TATA box binding protein (TBP). A total of 4 independent experiments were performed. **p £ 0.01, ***p £ 0.001. (B) RT-qPCR analysis of CNS-PGC-1a from H4 cells cotransfected with S1/S2 and the 2 independent shRNAs (ShPGC-1a-A and ShPGC-1a-B). mRNA levels were standardized using POLR2A and TBP. A total of 4 independent experiments were performed. *p £ 0.05, **p £ 0.01, ***p £ 0.001, ****p £ 0.0001. (C) RTqPCR analysis of PGC-1b from H4 cells cotransfected with S1/S2 and the 2 independent shRNAs (ShPGC-1a-A and ShPGC-1a-B). mRNA levels were standardized using POLR2A and TBP. A total of 3 independent experiments were performed showing that PGC-1b expression is not affected by PGC-1a shRNAs. ns 5 not significant. (D) Representative Western blotting showing PGC-1a and b-actin levels. PGC-1a levels are reduced in H4 cells cotransfected with S1/S2 and the 2 independent shRNAs (ShPGC-1a-A and ShPGC-1a-B). Bar graph represents the densitometric quantification of Western blots, n 5 3, *p < 0.05. (E) Luciferase assay from H4 cells 24 hours postinfection with indicated lenti-shRNAs and cotransfection with S1/S2. Six independent experiments were performed. ***p £ 0.001. ****p £ 0.0001. (F) Representative Western blots showing a-syn and b-actin levels from H4 cells cotransfected with S1/S2 and the 2 independent shRNAs (ShPGC-1a-A and ShPGC-1a-B). Bar graph represents the densitometric quantification of Western blots, n 5 4, **p < 0.01. Note that equal amounts of S1/S2 are produced in both Sh-scramble and ShPGC-1a conditions. (G) H4 cells 24 hours postinfection with indicated lenti-shRNAs and cotransfection with S1/S2 were assayed for caspase 3-7 activity. A total of 3 experiments were performed. ****p £ 0.0001. (H) At 24 hours postinfection with indicated lenti-shRNAs and cotransfection with S1/S2, cytotoxicity was assessed in H4 cells using the cell titer glow assay, which measures adenosine triphosphate levels in cells. Values are normalized to respective mock controls. ShPGC-1a-A and ShPGC-1a-B are presented in relation to the Sh-scramble control. A total of 3 independent experiments were performed, ****p £ 0.0001.
Aggregation of a-syn is a major hallmark of PD and is recapitulated in the A30P a-syn mouse model by protease-K-resistant a-syn fibrils mainly in the brainstem, midbrain, and spinal cord. 61 Interestingly, we found in the brainstem of A30P a-syn mice an agedependent decline of RG-PGC-1a and CNS-PGC-1a levels starting at 6 and 3 months of age, respectively (see Fig 1D, E) . To correlate PGC-1a downregulation with a-syn aggregation, we also analyzed the cortices of these mice, where widespread expression of a-syn is present but there is no occurrence of fibrils. In contrast to the brainstem, where the decrease of RG-PGC-1a is already manifest at 6 months of age, RG-PGC-1a downregulation in the cortex of A30P a-syn mice starts at 15 months of age (see Fig 1F) , which might be related to a later onset of a-syn aggregation processes in this area. Also, for the CNS-PGC-1a isoforms, we noted a reduction in expression levels that occurred later in the cortices (6 months of age) than in the brainstem (3 months of age; see Fig 1G) . Taken together, these results indicate an association between a-syn aggregation and PGC-1a downregulation.
To investigate whether the presence of a-syn oligomers in cell culture has a direct effect on PGC-1a transcript levels, we expressed a-syn oligomers and quantified RG-PGC-1a and CNS-PGC-1a mRNA levels using RT-qPCR. To determine oligomeric a-syn inside cells, we used a protein-fragment complementation assay where a-syn was fused to nonbioluminescent N-or Cterminal fragments of Gaussia princeps luciferase (S1 and S2) that reconstitute when brought together by a-syn/asyn interactions. 53, 62 The (patho)physiological validity of the a-syn protein complementation system and its comparison with nontagged wild-type a-syn using multiple methods was repeatedly shown before in previous studies. 53, 54, [62] [63] [64] These constructs were used to infect wildtype primary cortical neurons with adeno-associated virus (AAV), encoding either S1 or S2. Interestingly, expression of both RG-PGC-1a and CNS-specific isoforms were decreased when a-syn oligomers are present (see Fig 1H,  I ). A reduction of RG-PGC-1a was also detected in human H4 neuroglioma cells after cotransfection of S1 and S2 (see Fig 1J) . Of note, we did not observe a reduction in CNS-PGC-1a (see Fig 1K) in H4 cells when they were cotransfected with S1 and S2, possibly because levels of CNS-PGC-1a in H4 neuroglioma cells were barely above background levels. Collectively, RG-PGC-1a and CNS-PGC-1a deregulation in postmortem PD patient material, in A30P asyn transgenic mice, and in a cell culture models for asyn oligomerization strongly support a link between asyn oligomerization and deregulation of RG-PGC-1a and CNS-PGC-1a expression.
PGC-1a Knockdown Increases a-Synuclein Oligomerization
To directly link PGC-1a downregulation and a-syn oligomerization, we used lentiviral delivery of PGC-1a-shRNAs (ShPGC-1a-A and ShPGC-1a-B) for reduction of both RG-PGC-1a and CNS-PGC-1a expression. We then cotransfected human H4 cells with S1/S2 constructs to measure a-syn oligomerization. Successful and specific downregulation of PGC-1a isoforms was confirmed by RT-qPCR and Western blotting (Fig 3) . Interestingly, we found that RG-PGC-1a and CNS-PGC-1a silencing led to a 1.5-fold increase of a-syn oligomers, whereas no significant differences in a-syn protein levels were detected. Concurrently, knockdown of PGC-1a isoforms also resulted in an increase of a-syn-mediated toxicity.
To further validate the consequences of PGC-1a loss of function for a-syn oligomerization, we coinfected primary cortical neurons from both RG-PGC-1a deficient mice 52 and wild-type mice with AAV-S1 and AVV-S2 and observed 20% more a-syn oligomers in the RG-PGC-1a-deficient primary neurons (Fig 4A) . To exclude the possibility that the increase in a-syn oligomers is due to increased expression levels in S1 and S2 in the RG-PGC-1a KO condition, we performed Western blot analysis and detected comparable levels of S1 and S2 in both conditions (see Fig 4B) . However, no obvious increase in cytotoxicity was seen in the PGC-1a KO condition (data not shown). Together, these findings suggest that PGC-1a deficiency can promote a-syn oligomerization.
PGC-1a Ameliorates a-Synuclein Oligomerization
Because we observed PGC-1a downregulation in PD brains, in a-syn transgenic mice, and in a cell culture model for a-syn oligomerization, we asked whether overexpression of PGC-1a could rescue a-syn oligomerization. We found that cotransfection of RG-PGC-1a together with S1 and S2 dramatically reduced a-syn oligomers by approximately 50% and 70% after 24 hours and 36 hours, respectively (Fig 5A) . To ensure that PGC-1a is functionally active in our conditions, RTqPCR for the RG-PGC-1a target genes TFAM and TFEB was performed. A significant induction of TFAM and TFEB, when PGC-1a was cotransfected together with S1/S2, confirmed functionally active RG-PGC-1a (Fig 6) . The observed reduction in a-syn oligomers might partially be attributed to a small trend of PGC-1a affecting a-syn protein expression, as Western blot analysis revealed slightly reduced a-syn protein levels after 24 hours and 36 hours in the RG-PGC-1a condition compared to myc-control transfected S1/S2 H4 cells (see Fig  5) . PGC-1a has been previously reported to promote the elimination of huntingtin aggregates by activating TFEB, a master regulator of the autophagy-lysosome pathway (ALP). 31 To assess whether autophagy is involved in reduction of a-syn oligomers when PGC-1a is overexpressed, BacMam LC3B-GFP transduction was carried out. This system enables the expression of LC3B-GFP, ensuring efficient visualization of LC3-positive vesicles. LC3 staining was quantified using autophagy AUTO-COUNTER software, as published previously. 60 When S1/S2 was overexpressed, autophagy was reduced; however, RG-PGC-1a could rescue this effect by a strong upregulation of autophagy, suggesting that a-syn oligomers are specifically reduced due to RG-PGC-1a-mediated induction of autophagy. To determine whether RG-PGC1a is capable of rescuing a-syn-mediated toxicity, we measured cell viability after S1/S2 and RG-PGC-1a cotransfection. Notably, RG-PGC-1a could rescue a-syn mediated derogation in cell viability. To further support the idea that the ALP might contribute to RG-PGC-1a-related reduction in a-syn oligomers, H4 cells were cotransfected with S1 and S2 together with RG-PGC-1a or myc control plasmid and treated with the ALP inhibitor BAF A1 or DMSO. The reduction of a-syn oligomerization due to RG-PGC-1a was mainly abolished under the ALP inhibitor BAF A1 compared to the DMSO control, suggesting that an intact ALP is necessary for a RG-PGC-1a-related reduction in a-syn oligomers. Collectively, these data indicate that induction of RG-PGC-1a can reduce a-syn oligomerization and related a-syn-mediated toxicities.
Pharmacological Modulation of PGC-1a Alters asyn Oligomerization
To further validate the effect of PGC-1a on a-syn oligomerization, we chose a pharmacological approach to modulate PGC-1a activation. Resveratrol and AICAR have been described as potent PGC-1a activators. 65, 66 Resveratrol activates PGC-1a through the upstream activators, sirtuin1 and adenosine monophosphate-activated protein kinase (AMPK), 65, 67, 68 and AICAR activates PGC-1a by promoting AMPK-mediated phosphorylation. 69, 70 We found that both resveratrol and AICAR treatments resulted in a robust decrease of a-syn oligomers after 24 hours of treatment in S1/S2-transfected H4 cells (Fig 7) . In contrast to PGC-1a activation, treatment with the PGC-1a inhibitor compound C, which inhibits the upstream PGC-1a activator AMPK, 71 strongly promoted a-syn oligomerization without changes in S1/S2 protein contents. Concurrently, we observed a reduction in cytotoxicity by resveratrol and AICAR treatment compared to DMSO control. To test whether resveratrol and AICAR reduce a-syn oligomerization truly via PGC-1a, we downregulated PGC-1a by lentiviral delivery of PGC-1a shRNAs (ShPGC-1a-A and ShPGC-1a-B) in H4 cells. We then cotransfected H4 cells with S1/S2 and treated them with resveratrol, AICAR, or DMSO control. In contrast to application of scramble lentivirus, silencing of RG-FIGURE 6: Peroxisome proliferator-activated receptor c coactivator 1a (PGC-1a) overexpression restores the expression levels of PGC-1a target genes upon a-synuclein overexpression. mRNA levels of PGC-1a target genes TFAM (A) and TFEB (B) in H4 cotransfected with a-syn-hGLuc1 (S1)/asyn-hGLuc2 (S2) for 48 hours together with myc control plasmid (black columns) or vector encoding RG-PGC-1a (gray columns). mRNA levels were standardized using polymerase (RNA) II polypeptide A and TATA box binding protein. *p < 0.05, **p < 0.01.
PGC-1a and CNS-PGC-1a abrogated the a-syn oligomer reducing effect of resveratrol and AICAR, thus verifying that resveratrol and AICAR do not reduce asyn oligomers in PGC-1a-deficient cells. Because resveratrol had the strongest effect on asyn oligomer reduction in our experimental setting, we asked whether this reduction evolves over time, and thus treated S1/S2-transfected H4 cells for different time periods. A small reduction in a-syn oligomers was already found at 6 hours of resveratrol treatment, and progressed further over time (Fig 8A) . Next, we examined whether the reduction of a-syn oligomers depends on the concentration of resveratrol. Luciferase assays verified a dosedependent decrease of a-syn oligomers under resveratrol treatment (see Fig 8B) . Thus, reduction of a-syn oligomers by resveratrol occurs in a time-and dose-dependent manner. Together, PGC-1a overexpression or PGC-1a pharmacological activation is capable of reducing a-syn oligomerization.
RG-PGC-1a-Deficient Neurons Are More Vulnerable to Extracellular a-syn Oligomers We and others have previously shown that exogenous addition of a-syn oligomers can induce Lewy body-like pathology and related toxicities. 8, [72] [73] [74] Cell to cell transmission of pathological a-syn and spreading of asyn pathology have been demonstrated in a number of studies. 1, [75] [76] [77] To determine whether RG-PGC-1a deficient cells are more vulnerable to exogenous addition of a-syn oligomers, we treated primary neurons from wild-type or RG-PGC-1a-deficient mice with conditioned media (CM), either containing a-syn oligomers S1/S2 or from mock transfected H4 cells. After 2 or 3 days of incubation, we measured luciferase activity indicative of a-syn oligomers inside primary neurons. Strikingly, we found that RG-PGC-1a-deficient neurons had remarkably higher levels of a-syn oligomers compared to neurons from wild-type mice after 72 hours of incubation (Fig 9C) , with a trend already visible at 24 hours (see Fig 9A) , suggesting RG-PGC-1a-deficient cells are less capable of handling a-syn oligomers. Interestingly, in RG-PGC-1a-deficient cells, we saw a strong increase in toxicity when they were treated with CM containing a-syn oligomers compared to wild-type neurons, indicating a higher vulnerability of RG-PGC-1a-deficient neurons to extracellular a-syn oligomer-mediated toxicity (see Fig 9B, D) . Thus, RG-PGC-1a deficiency potently exacerbates extracellular asyn oligomer-mediated toxicity
Discussion
The present study provides the first direct evidence that PGC-1a deregulation and a-syn aggregation might form a vicious circle influencing and potentiating each other: PGC-1a reduces a-syn oligomerization and ameliorates a-syn-mediated toxicity. In contrast, a-syn oligomerization is increased in RG-PGC-1a-deficient neurons and neuroglioma cells where PGC-1a is knocked down via PGC-1a shRNAs. Moreover, PGC-1a appears to be deregulated in human PD brain, in a-syn transgenic mice, and in an in vitro cell culture model for a-syn oligomerization, further strengthening the idea that PGC1a deregulation influences a-syn oligomer-mediated toxicity and vice versa. Finally, we found that RG-PGC-1a-deficient neurons are more vulnerable for extracellular asyn oligomer-mediated toxicity. PGC-1a has been found to be widely expressed in the brain. 78 Recent studies highlight the importance of tightly controlling the expression levels of PGC-1a. Nonphysiological overexpression of PGC-1a in dopaminergic neurons induces degeneration of dopaminergic neurons in the rat nigrostriatal system. 44 Cardiac overexpression of PGC-1a causes severe abnormalities in the myocyte architecture due to extensive mitochondrial proliferation. 79, 80 In the skeletal muscle, PGC-1a overexpression enhances not only mitochondrial biogenesis but also respiration uncoupling, leading to muscle atrophy. 81 In contrast, PGC-1a expression within physiological levels improves insulin sensitivity in skeletal muscle. 82 Our study further underlines a critical need for maintaining physiological levels of PGC-1a activity. In contrast to excessive levels of PGC-1a, underexpression of PGC-1a might have detrimental effects on neuronal survival. We found reduced expression of RG-PGC-1a in the SN of PD patients compared to non-PD controls. Because RG-PGC-1a transcript levels were normalized to housekeeping genes POLR2A and TBP, it is not likely that the reduction in RG-PGC1a levels is solely due to neuronal loss in the SN of PD patients. The downregulation of RG-PGC-1a is completely associated with the presence of PD. Especially age and gender did not engage any relevant statistical influence on the expression level in our RG-PGC-1a data, as we could demonstrate by the application of a linear mixed effects model. Interestingly, primary neuronal cultures showed reduced levels of both RG-PGC-1a and CNS-PGC-1a when a-syn oligomers were overexpressed. Our results are also in accordance with a prior study demonstrating that genes expressed in response to PGC-1a are underexpressed in PD patients. 43 Moreover, in a transgenic mouse model overexpressing human A30P a-syn, which does not display nigral cell loss, [49] [50] [51] 83 we demonstrated a downregulation of both RG-PGC-1a and CNS PGC-1a in the brainstem of transgenic mice overexpressing human A30P a-syn compared to wild-type mice at early time points. In contrast, in the cortices of a-syn transgenic mice, where widespread expression of a-syn is present but there is no occurrence of pathogenic fibrils, 61 RG-PGC-1a and CNS PGC-1a were deregulated at later time points, indicating a link between a-syn aggregation and PGC-1a deregulation. Most importantly, downregulation of RG-PGC-1a and CNS-PGC-1a could be modeled in cell culture using lentiviral vectors encoding shRNA directed against PGC-1a, leading to a strong induction of a-syn oligomerization and a subsequent increase in toxicity. Moreover, neurons of RG-PGC-1a-deficient mice also displayed increased oligomerization of a-syn, collectively, pointing to a direct pathophysiological consequence of PGC-1a underexpression on increased asyn oligomerization. We speculate that insufficient function or underexpression of RG-or CNS-PGC-1a might predispose to a-syn aggregation, and could therefore be a potential risk factor for PD. Conversely, it is also possible that increased ROS production during aging leads to increased a-syn aggregation, with a resulting downregulation of RG-or CNS-PGC-1a, which might further promote a-syn aggregation and toxicity.
Along the same line of evidence, a direct action of asyn on the PGC-1a promoter has been reported, leading to PGC-1a repression. 46 An intriguing possibility would be that a-syn aggregates or oligomers bind more effectively to the promoter of PGC-1a than nonaggregated a-syn, thereby explaining the earlier downregulation of different PGC-1a forms in the brainstem of transgenic A30P a-syn mice that is mostly and earliest affected by a-syn aggregates. Interestingly, downregulation of PGC-1a has also been observed in human HD brain and in mouse striatum. 55 Several studies reported downregulation of PGC-1a mRNA with mutant huntingtin implicated in the transcription of PGC1a, 30, [84] [85] [86] [87] whereas pharmacologic/transcriptional activation of PGC-1a had beneficial effects in models of HD. [88] [89] [90] Furthermore, in PD downregulation of the master regulator of mitochondrial biogenesis PGC-1a might be FIGURE 9: Peroxisome proliferator-activated receptor c coactivator 1a reference gene (RG-PGC-1a) deficiency in primary neurons increases a-synuclein oligomer accumulation and toxicity. (A) Luciferase assay from wild-type (1/1) or RG-PGC-1a 2/2 primary neurons incubated for 48 hours with conditioned media from H4 cells transfected with mock or a-syn-hGLuc1 (S1)/a-syn-hGLuc2 (S2), *p £ 0.05, **p £ 0.01, ***p £ 0.001, ****p £ 0.0001, n 5 3. (B) Primary neurons from 1/1 or RG-PGC-1a 2/2 mice were assayed for release of adenylate kinase using the ToxiLight assay after 48 hours of incubation with conditioned media from H4 cells transfected with mock or S1/S2. Three independent experiments were performed, **p £ 0.01, ***p £ 0.001. (C) Luciferase assay from 1/1 or RG-PGC-1a 2/2 primary neurons incubated for 72 hours with conditioned media from H4 cells transfected with mock or S1/S2, n 5 3, *p £ 0.05, **p £ 0.01, ***p £ 0.001, ****p £ 0.0001. (D) Primary neurons from 1/1 or RG-PGC-1a 2/2 mice were assayed for release of adenylate kinase using the ToxiLight assay after 72 hours of incubation with conditioned media from H4 cells transfected with mock or S1/S2. Three independent experiments were performed, ***p £ 0.0001.
connected to the well-characterized mitochondrial dysfunction observed in PD patients and respective experimental models. 18, 20, [91] [92] [93] [94] [95] Together, PGC-1a deregulation and a-syn aggregation are clearly negatively influencing each other, which might also occur in the brains of PD patients, leading to a vicious circle and potentially contributing to the etiology of PD. In addition to our findings on PGC-1a deregulation on a transcriptional level, we also investigated whether restoration of PGC-1a function using both genetic and pharmacological approaches could rescue a-syn oligomerization and related toxicities. We found that RG-PGC-1a is capable of reducing a-syn oligomers and related toxicity. These results are in accordance with previous studies describing PGC-1a to be protective in the context of PD; PGC-1a increases the survival of neurons overexpressing the mutated A53T a-syn 47 and in the MPTP mouse model. 96 Furthermore, the repression of PGC-1a by PARKin interacting substrate (PARIS) kills dopaminergic neurons in vivo, and its reactivation prevents this loss. 45 Several mechanisms could underlie the observed protective effect of PGC-1a on a-syn oligomerization and toxicity. First, amelioration of mitochondrial function and reduction of ROS by PGC-1a could be beneficial, concerning a-synmediated toxicity, because overexpression of wild-type or mutant a-syn increases the rate of intracellular ROS. 97, 98 PGC-1a has already been shown to regulate the expression of ROS-detoxifying enzymes such as SOD2 and Gpx. 30 Thus, a direct effect of PGC-1a on ROS metabolism could explain the protective effect on a-syn-mediated toxicity. Second, beneficial effects of PGC-1a could result from restoration of the PGC-1a target genes such as the subunits of complex I to V of the mitochondrial electron chain transport, genes involved in oxidative phosphorylation and mitochondrial biogenesis that are reduced in PD patients. 43 A third explanation for a protective effect of PGC-1a on a-syn oligomerization and toxicity might be through activation of the ALP. A recent study emphasized a role for PGC-1a in the elimination of huntingtin aggregation by activating TFEB, a master regulator of the ALP. 31 PGC-1a transactivation resulted in enhanced ALP activity through the activation of TFEB. In our cell culture experiments, we observed an increase of the LC3-positive vesicles when PGC-1a is overexpressed together with asyn. This increase of LC3-positive vesicles was accompanied by a decrease of asyn oligomers. This reduction of a-syn oligomers could only be observed in cells with an intact ALP, because treatment with ALP inhibitor BAF A1 abolished this effect. These results suggest that autophagy might be one potential but possibly not the only mechanism involved in the PGC-1a-dependent reduction of a-syn oligomers.
Furthermore, in midbrain dopamine neurons, TFEB activation has been shown to be directly inhibited by asyn via blockage of nuclear translocation of TFEB leading to inhibition of the ALP. 99 However, the exact role of autophagy in this process warrants further investigation. In conclusion, this study suggests that PGC-1a can ameliorate a-syn oligomerization and related toxicities. Insufficient function or underexpression of RG-or CNS-PGC-1a in the PD brain might accelerate a-syn oligomerization and contribute to neurodegenerative disease. Restoration of PGC-1a function might thus be a novel approach for the development of effective drugs for the treatment of PD and related synucleinopathies.
